Posted by | January 22, 2012 20:56 | Filed under: Top Stories

Satavex, which contains delta 9-THC and cannabidiol, the main ingredients in marijuana, could be approved by the FDA by the end 0f 2013 for use treating cancer pain. It’s already approved in Canada and New Zealand and in eight European countries.

FDA approval would represent an important milestone in the nation’s often uneasy relationship with marijuana, which 16 states and the District of Columbia already allow residents to use legally with doctors’ recommendations. The U.S. Drug Enforcement Administration categorizes pot as a dangerous drug with no medical value, but the availability of a chemically similar prescription drug could increase pressure on the federal government to revisit its position and encourage other drug companies to follow in GW Pharma’s footsteps.

Click here for reuse options!
Copyright 2012 Liberaland
By: Alan

Alan Colmes is the publisher of Liberaland.